PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Tytuł artykułu

N-Metyloformamid : dokumentacja proponowanych dopuszczalnych wielkości narażenia zawodowego

Treść / Zawartość
Identyfikatory
Warianty tytułu
EN
N-Methylformamide : documentation of proposed values of occupational exposure limits (OELs)
Języki publikacji
PL
Abstrakty
PL
N-Metyloformamid to bezbarwna ciecz o amoniakalnym zapachu stosowana jako rozpuszczalnik i półprodukt do reakcji chemicznych. Nie ma danych o narażeniu ludzi w warunkach zawodowych w Polsce.N-Metyloformamid bardzo dobrze wchłania się do organizmu człowieka. Wartości LD50 dla N-metyloformamidu podanego zwierzętom różnymi drogami są zbliżone (2 600 ÷ 4 000 mg/kg mc.). Po jednorazowym lub krótkoterminowym podawaniu związku w dawkach 100 ÷ 1 200 mg/kg mc. obserwowano nasilające się objawy uszkodzenia wątroby. Największe stężenie nie powodujące skutków szkodliwych (NOAEC) wynosiło 120 mg/m³ (dwutygodniowe inhalacyjne narażenie szczurów). Przy stężeniach 320 mg/m³ oraz 980 mg/m³ obserwowano nasilające się skutki działania hepatotoksycznegoN-metyloformamidu. Działanie toksyczne na wątrobę przyjęto za skutek krytyczny. Brakuje danych o działaniu podprzewlekłym, przewlekłym oraz rakotwórczym związku na zwierzęta laboratoryjne.N-Metyloformamid nie działał mutagennie i genotoksycznie, ale powodował skutki embriotoksyczne i teratogenne. Za podstawę do wyznaczenia wartości NDS dla N-metyloformamidu przyjęto wartość NOAEC (120 mg/m³), a wartość NDSN-metyloformamidu wyliczono na poziomie 3,3 mg/m³. Nie ma podstaw do wyznaczenia wartości najwyższego dopuszczalnego stężenia chwilowego (NDSCh) oraz dopuszczalnego stꬿenia w materiale biologicznym (DSB). Zaproponowano oznakowanie związku jako „Ft” (substancja o działaniu szko¬dliwym na rozrodczość) oraz „skóra” (wchłanianie substancji przez skórę może być tak samo istotne, jak przy narażeniu drogą oddechową). Zakres tematyczny artykułu obejmuje zagadnienia zdrowia oraz bezpieczeństwa i higieny środowiska pracy będące przedmiotem badań z zakresu nauk o zdrowiu oraz inżynierii środowiska.
EN
N-Methylformamide is a colorless liquid with an ammoniacal odor, used as a solvent and an intermediate for chemical reactions. There are no data on occupational exposure in Poland. N-Methylformamide is very well absorbed into the human body. The LD50 values for N-methylformamide administered to animals in various routes are similar (2600–4000 mg/kg bw). After single or short-term administration of the compound in doses of 100–1200 mg/kg bw. worsening symptoms of liver damage have been observed. No-observed adverse effect concentration (NOAEC) was established at 120 mg/m³ (two-week inhalation exposure in rats). Increase of hepatotoxic effect of N-methylformamide were observed at concentrations of 320 mg/m³ and 980 mg/m³ . There are no data on the sub-chronic, chronic and carcinogenic effects of the compound in laboratory animals. N-Methylformamide was not mutagenic and genotoxic. It caused embryotoxic and teratogenic effects. The NOAEC value (120 mg/m³ ) was used as the basis for determining the MAC (maximum acceptable concentration) value for N-methylformamide, and the MAC value for N-methylformamide was calculated at 3.3 mg/m³ . There are no basis to determine the short-term value (STEL) and biological limit value (BLV). It has been proposed to label the compound as ˝Ft˝ (toxic for repoduction) and ˝skin˝ (skin absorption of the substance may be as important as inhalation exposure). This article discusses the problems of occupational safety and health, which are covered by health sciences and environmental engineering.
Rocznik
Strony
15--49
Opis fizyczny
Bibliogr. 85 poz., rys., tab.
Twórcy
  • Uniwersytet Medyczny w Łodzi 90-151 Łódź, ul. J. Muszyńskiego 1 POLAND
  • Uniwersytet Medyczny w Łodzi 90-151 Łódź, ul. J. Muszyńskiego 1 POLAND
  • Uniwersytet Medyczny w Łodzi 90-151 Łódź, ul. J. Muszyńskiego 1 POLAND
Bibliografia
  • 1. ACGIH (2018). American Conference of Governmental Industrial Hygienists. Guide to occupational exposure values. Complied by ACGIH, Cincinnati, p. 143.
  • 2. ACGIH (2019). American Conference of Governmental Industrial Hygienists. TLVs and BEIs based on the documentation of the Threshold Limit Values for chemical substances and physical agents and Biological Exposure Indices. ACGIH, Cincinnati.
  • 3. Arundel C., Bock S., Brock W.A., Tofilon P.J. (1987). Radiosensitization of primary human tumor cell cultures by N-methylformamide. Int. J. Radiat. Oncol. Biol. Phys. 13(5), 753–757.
  • 4. Arundel C.M., Leith J.T., Lee E.S., Leite D.V., Glicksman A.S. (1986). Potentiation of in vitro cytotoxic effects of misonidazole on human colon tumor cells by the differentiation-inducing agent N-methylformamide. Int. J. Radiat. Oncol. Biol. Phys. 12(8), 1429–1432.
  • 5. Atkinson R. (1987). Structure-activity relationship for the estimated of rate constants for the gas-phase reactions of hydroxyl radicals with organic compounds. Int. J. Chem. Kinet. 19, 799–828 [cyt. za: Kennedy 2001].
  • 6. Bipp H., Kieczka H. (2018). Formamides. [W:] Ullmann’s encyclopedia of industrial chemistry. Weinheim, Wiley-VCH, [https:// doi.org/10.1002/14356007.a12_001, data dostępu: 16.03.2020].
  • 7. Braunsteiner H. (1954). Antileukämische Wirkung von N-Methylformamid. Klin. Wochenschr. 32, 611–612 [cyt. za: Rowinsky i in. 1988].
  • 8. Brindley C., Gescher A., Harpur E.S., Ross D., Slack J.A., Threadgill M.D., Whitby H. (1982). Studies of the pharmacology of N-methylformamide in mice. Cancer Treat. Rep. 66(11), 1957–1965.
  • 9. ChemIDplus (2020). A Toxnet database. Komputerowa baza danych toksykologicznych.
  • 10. Clagett-Carr K., Sarosy G., Plowman J., Hoth D.F., Leyland-Jones B. (1988). N-methylformamide: cytotoxic, radiosensitizer, or chemosensitizer. J. Clin. Oncol. 6(5), 906–918.
  • 11. Clarke D.A., Philips F.S., Strenberg S.S., Barclay R.K., Stock C.C. (1953). Effects of N-methylformamide and related compounds in mouse sarcoma 180. Proc. Soc. Exp. Biol. Med. 84(1), 203–207 [cyt. za: Rowinsky i in. 1988].
  • 12. Cordeiro R.F., Savarese T.M. (1984). Reversal by L-cysteine of the growth inhibitory and glutathione-depleting effects of N-methylformamide and N,N-dimethylformamide. Biochem. Biophys. Res. Commun. 122(2), 798–803.
  • 13. Cucco C., D’Agnano I., Marangolo M., Candiloro A., Zupi G. (1991). Importance of cell cycle perturbations on the effectiveness of N-methylformamide and anti-neoplastic drugs in combination. Cell Prolif. 24(3), 293–303.
  • 14. Del Bufalo D., Bucci B., D’Agnano I., Zupi G. (1994). N-Methylformamide as a potential therapeutic approach in colon cancer. Dis. Colon. Rectum. 37(2 Suppl), S133–137.
  • 15. ECHA (2020). N-Methylformamide. Brief profile 28.02.2020 [http://echa.europa].
  • 16. Eisenhauer E.A., Weinerman B.H., Kerr I., Quirt I. (1986). Toxicity of oral N-methylformamide in three phase II trials: a report from the National Cancer Institute of Canada Clinical Trials Group. Cancer Treat. Rep. 70(7), 881–883.
  • 17. Ethel Browning’s toxicology and metabolism of industrial solvents (1990). [Red.] R. Snyder. 2nd ed. Vol. II: Nitrogen and phosphorus solvents. Elsevier, Amsterdam, New York, Oxford, p. 172–175 [cyt. za: HSDB 2020; PubChem 2020].
  • 18. Eton O., Bajorin D.F., Casper E.S., Houghton A.N. (1991). Phase II trial of N-methylformamide in patients with metastatic melanoma. Invest. New Drugs 9(1), 97–100.
  • 19. Ettinger D.S., Orr D.W., Rice A.P., Donehower R.C. (1985). Phase I study of N-methylformamide in patients with advanced cancer. Cancer Treat. Rep. 69(5), 489–493.
  • 20. Ferenz R.L., Burgess B.A., Stula E.F., Kennedy G.L. (1984). Inhalation toxicity of N-methylformamide in the rat. Toxicologist 4, 65 [cyt. za: Kennedy 1986].
  • 21. Furst A., Cutting W.C., Gross H. (1955). Retardation of growth of Ehrlich ascites tumor by formamides and related compounds. Cancer Res. 15(5), 294–299 [cyt. za: Rowinsky i in. 1988].
  • 22. Gescher A., Gibson N.W., Hickman J.A., Langdon S.P., Ross D., Atassi G. (1982). N-Methylformamide: antitumour activity and metabolism in mice. Br. J. Cancer 45(6), 843–850.
  • 23. Harpur E.S., Langdon S.P., Fathalla S.A., Ishmael J. (1986). The antitumour effect and toxicity of cis-platinum and N-methylformamide in combination. Cancer Chemother. Pharmacol. 16(2), 139–147.
  • 24. Health Council of the Netherlands (2011). N-Methylformamide: evaluation of the carcinogenicity and genotoxicity. Subcommittee on the Classification of Carcinogenic Substances of the Dutch Expert Committee on Occupational safety, a Committee of the Health Council of the Netherlands. No. 2011/02OSH, The Hague. Raport dostępny na stronie www. healthcouncil.nl.
  • 25. Hemmerly J., Demerec M. (1955). Test of chemicals for mutagenicity. Cancer Res. 15 (Suppl. 3), 69–75 [cyt. za: ECHA 2020].
  • 26. HSDB (2020). Hazardous Substances Data Bank – komputerowa baza danych. N-Methylformamide. National Library of Medicine, Bethseda, Maryland [data dostępu: 5.03.2020].
  • 27. Hyland R., Gescher A., Thummel K., Schiller C., Jheeta P., Mynett K., Smith A.W., Mráz J. (1992). Metabolic oxidation and toxification of N-methylformamide catalyzed by the cytochrome P450 isoenzyme CYP2E1. Mol. Pharmacol. 41(2), 259–266.
  • 28. IFA (2020). N-Methylformamide. IFA GESTIS Substance Database. IFA Institute for Occupational Safety and Health of the German Social Accident Insurance. 11.03.2020.
  • 29. Iwakawa M., Milas L., Hunter N., Tofilon P.J. (1987). Modification of tumor and normal tissue radioresponse in mice by N-methylformamide. Int. J. Radiat. Oncol. Biol. Phys. 13(1), 55–60.
  • 30. Jacobs G.A., Martens M.A. (1989). An objective method for the evaluation of eye irritation in vivo. Food Chem. Toxicol. 27(4), 255–258 [cyt. za: ECHA 2020] .
  • 31. Kelich S.L., Mercieca M.D., Pohland R.C. (1995). Developmental toxicity of N-methylformamide administered by gavage to CD rats and New Zealand white rabbits. Fundam. Appl. Toxicol. 27(2), 239–246.
  • 32. Kennedy G.L. Jr (1986). Biological effects of acetamide, formamide, and their monomethyl and dimethyl derivatives. Crit. Rev. Toxicol. 17(2), 129–182.
  • 33. Kennedy G.L. Jr (2001). Biological effects of acetamide, formamide, and their monomethyl and dimethyl derivatives: an update. Crit. Rev. Toxicol. 31(2), 139–222.
  • 34. Kennedy G.L. Jr, Ferenz R.L., Burgess B.A., Stula E.F. (1990). 2-Week inhalation study of N-monomethylformamide in rats. Fundam. Appl. Toxicol. 14(4), 810–816.
  • 35. Kestell P., Gescher A., Slack J.A. (1985). The fate of N-methylformamide in mice. Routes of elimination and characterization of metabolites. Drug Metab. Dispos. 13(5), 587–592.
  • 36. Kestell P., Gledhill A.P., Threadgill M.D., Gescher A. (1986). S-(N-Methylcarbamoyl)-N-acetylcysteine: a urinary metabolite of the hepatotoxic experimental antitumour agent N-methylformamide (NSC 3051) in mouse, rat and man. Biochem. Pharmacol. 35(14), 2283–2286.
  • 37. Kestell P., Threadgill M.D., Gescher A., Gledhill A.P., Shaw A.J., Farmer P.B. (1987). An investigation of the relationship between the hepatotoxicity and the metabolism of N-alkylformamides. J. Pharmacol. Exp. Ther. 240(1), 265–270.
  • 38. Kröger H., Grätz R., Grahn H. (1983). Influence of N-methylformamide on the development, the NAD synthesis, and the activity of the ADPR transferase of rat embryos. Experientia 39(1), 93–94.
  • 39. Laitarenko G.V., Makarova G.F., Tsyganok V.M. (1992). [Experimental substantiation of the maximum permissible esposure level of N-methylformamide in reservoir water]. Gig. Sanit. 2, 30–32 [in Russian], [cyt. za: Health Council… 2011].
  • 40. Langdon S.P., Chubb D., Gescher A., Hickman J.A., Stevens M.F. (1985a). Studies on the toxicity of the antitumour agent N-methylformamide in mice. Toxicology 34(2), 173–183.
  • 41. Langdon S.P., Hickman J.A., Gescher A., Stevens M.F., Chubb D., Vickers L.M. (1985b). N-Methylformamide (NSC 3051): a potential candidate for combination chemotherapy. Eur. J. Cancer Clin. Oncol. 21(6), 745–752.
  • 42. Laudonio N., Zupi G., Erba E., Leonetti C., D’Incalci M. (1990). Synergism between 5-fluorouracil and N-methylformamide in HT29 human colon cancer line. Br. J. Cancer. 61(3), 377–381.
  • 43. Leith J.T., Lee E.S., Leite D.V., Glicksman A.S.(1986). Enhanced X ray sensitivity of human colon tumor cells by combination of N-methylformamide with chemotherapeutic agents. Int. J. Radiat. Oncol. Biol. Phys. 12(8), 1423–1427.
  • 44. Leith J.T., Lee E.S., Vayer A.J. Jr, Dexter D.L., Glicksman A.S. (1985). Enhancement of the responses of human colon adenocarcinoma cells to X-irradiation and cis-platinum by N-methylformamide (NMF). Int. J. Radiat. Oncol. Biol. Phys. 11(11), 1971–1976.
  • 45. Lewis R.J. (1996). Sax’s dangerous properties of industrial materials. 9th ed., vol. 1–3, Van Nostrand Reinhold, New York, p. 2243 [cyt. za: HSDB 2020; PubChem 2020].
  • 46. Masuda Y., Nakayama N., Yasoshima M. (1986). The effects of diethyldithiocarbamate on the hepatotoxic action and antitumor activity of N-methylformamide in mice. Jpn. J. Pharmacol. 40(4), 541–550.
  • 47. Matook G.M., Spremulli E.N., Birmingham B.K., Calabresi P., Griffiths W.C. (1984). Tissue analysis of N-methylformamide: organ distribution. J. Anal. Toxicol. 8(3), 146–148.
  • 48. McGuire W.P., Blessing J.A., Berek J.S., Munoz A. (1990a). Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer. A Gynecologic Oncology Group study. Invest. New Drugs. 8(2), 191–194.
  • 49. McGuire W.P., Blessing J.A., Hatch K.D., Berman M.L. (1990b). Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced squamous cancer of the cervix.A Gynecologic Oncology Group study. Invest. New Drugs. 8(2), 195–197.
  • 50. McVie J.G., ten Bokkel Huinink W.W., Newlands E., Simonetti G., Slack J. (1983). Phase I studies and clinical pharmacology of N-methylformamide (NSC-3051, NMF). Proc. Am. Soc. Clin. Oncol. 2, 34 (abstr) [cyt. za: Clagett-Carr i in. 1988; Rowinsky i in. 1989].
  • 51. McVie J.G., ten Bokkel Huinink W.W., Simonetti G., Dubbelman R. (1984). Phase I trial of N-methylformamide. Cancer Treat. Rep. 68(4), 607–610.
  • 52. Merkle J, Zeller H. (1980). [Studies on acetamides and formamides for embryotoxic and teratogenic activities in the rabbit (author’s transl)]. Arzneim. Forsch. 30(9),1557–1562 [in German], [cyt. za: HSDB 2020; Kennedy 1986].
  • 53. Mutlib A., Jiang P., Atherton J., Obert L., Kostrubsky S., Madore S., Nelson S. (2006). Identification of potential genomic biomarkers of hepatotoxicity caused by reactive metabolities of N-methylformamide: application of stable isotope labeled compounds in toxicogenomic studies. Chem. Res. Toxicol. 19(10), 1270–1283.
  • 54. Myers W.P.L., Karnofsky D.A., Burchenal J.H. (1956). The hepatotoxic action of N-methylformamide in man. Cancer 9(5), 949–954.
  • 55. NCI (1983). National Cancer Institute. Clinical brochure: N-methylformamide (NMF) NSC 3051. Division of Cancer Treatment, National Cancer Institute, Bethesda, MD [cyt. za: Clagett-Carr i in. 1988; Rowinsky i in. 1988].
  • 56. Newman K.N., Meeks R.G., Frick S. (1981). Preclinical intravenous toxicity study of N-methylformamide (NSC-3051) in CDF1 mice and beagle dogs. NTI3 Rep. No. PB82-197823, National Technical Information Service, Springfield, Va. [cyt. za: Kennedy 1986].
  • 57. NTP (1990). National Toxicology Program. Testing status of N-methylformamide [http://ntp.niehs.nih.gov/ cyt. za: Health Council... 2011].
  • 58. NTP (2008). National Toxicology Program. Salmonella microsome assay; study ID: 220260 [http://ntp-apps.niehs.nih. gov/ cyt. za: ECHA 2020].
  • 59. O’Dwyer P.J., Donehower M., Sigman L.M., Fortner C.L., Aisner J., Van Echo D.A. (1985). Phase I trial of N-methylformamide (NMF, NSC 3051). J. Clin. Oncol. 3(6), 853–857.
  • 60. Oettel H., Frohberg H. (1965). Zum Nachweis teratogener Wirkung im Tierversuch. 4. Int. Congress Int. Feder Hyh. Prev. Med.; BASF AG, Ludwigshafen [cyt. za: ECHA 2020].
  • 61. Pearson P.G., Gescher A., Harpur E.S. (1987a). Hepatotoxicity of N-methylformamide in mice. I. Relationship to glutathione status. Biochem. Pharmacol. 36(3), 381–384.
  • 62. Pearson P.G., Gescher A., Harpur E.S., Threadgill M.D. (1987b). Hepatotoxicity of N-methylformamide in mice. II. Covalent binding of metabolites of [14C]-labelled N-methylformamide to hepatic proteins. Biochem. Pharmacol. 36(3), 385–390.
  • 63. Peh J. (1974). Study on the mutagenic effects of formamides and acetamides in the dominant lethal test. Chromosome aberrations by industrials and vinyl chloride toxicity. Proccedings of 2nd International Symposium, Milano [cyt. za: ECHA 2020].
  • 64. Potter M., Law L.W. (1957). Studies of a plasma-cell neoplasm of the mouse. I. Characterization of neoplasm 70429, including its sensitivity to various antimetabolites with the rapid development of resistance to azaserine, DON, and N-methylformamide. J. Natl. Cancer Inst. 18(3), 413–441 [cyt. za: Rowinsky i in. 1988].
  • 65. PubChem (2020). Database. N-Methylformamide [https:// pubchem.ncbi.nim.nih.gov].
  • 66. Rajdev L., Yu Z.F., Wadler S., Weller E., Kahn S.B., Tormey D., Skeel R., Wiernik P.H. (2001). N-Methylformamide in advanced squamous cancer of the uterine cervix: an Eastern Cooperative Oncology Group phase II trial. Invest. New Drugs. 19(3), 233–237.
  • 67. Rickard L.B., Driscoll C.D., Kennedy G.L. Jr, Staples R.E., Valentine R. (1995). Developmental toxicity of inhaled N-methylformamide in the rat. Fundam. Appl. Toxicol. 28(2), 167–176.
  • 68. Roll R., Baer F. (1967). The teratogenic effects of monomethylformamide in pregnant mice. Arzneim. Forsch. 17, 610–614 [cyt. za: ECHA 2020].
  • 69. Rowinsky E.K., Grochow L.B., Hantel A., Ettinger D.S., Vito B.L., Donehower R.C. (1989). Assessment of N-methylformamide (NMF ) administered orally on a three times weekly schedule: a phase I study. Invest. New Drugs 7(4), 317–325.
  • 70. Rowinsky E.K., Noe D.A., Orr D.W., Grochow L.B., Ettinger D.S., Donehower R.C. (1988). Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity. J. Natl. Cancer. Inst. 80(9), 671–678.
  • 71. Rozporządzenie Parlamentu Europejskiego i Rady (WE) nr 1272/2008 z dnia 16 grudnia 2008 r. w sprawie klasyfikacji, oznakowania i pakowania substancji i mieszanin, zmieniające i uchylające dyrektywy 67/548/EWG i 1999/45/WE oraz zmieniające rozporządzenie (WE) nr 1907/2006. Dz. Urz. UE L 353 z 31.12.2008 z późn. zm. [Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (Text with EEA relevance)].
  • 72. Shaw A.J., Gescher A., Mráz J. (1988). Cytotoxicity and metabolism of the hepatotoxin N-methylformamide and related formamides in mouse hepatocytes. Toxicol. Appl. Pharmacol. 95(1), 162–170.
  • 73. Sigma-Aldrich (2019). N-Methylformamide. Karta charakterystyki. Aldrich-473936.
  • 74. Spremulli E.N., Dexter D.L., Cummings F.J.,Wieman M., Salvatore J., Smith D., Matook G., Vrabtree G.H., Griffits H., Calabresi P. (1983). Phase I clinical and pharmacological studies of monomethylformamide (N-MF). Proc. Am. Soc. Clin. Oncol. 2, 24, (abstr.) [cyt. za: Clagett-Carr i in. 1988; Rowinsky i in. 1989].
  • 75. Sternberg C.N., Yagoda A. (1985). N-Methylformamide-induced hypophosphatemia. Cancer Treat. Rep. 69(3), 343–344.
  • 76. Stula E.F., Krauss W.C. (1977). Embriotoxicity in rats and rabbits from cutaneous application of amide-type solvents and substituted ureas. Toxicol. Appl. Pharmacol. 41(1), 35–55.
  • 77. The Merck Index: an encyclopedia of chemicals, drugs, and biologicals (2001). M.J. O’Neil (ed.). 13th ed., Whitehouse Station, NJ, Merck and Co., p. 1189.
  • 78. ThermoFisher Scientific (2018). N-Methylformamide. Safety Data Sheet.
  • 79. Threadgill M.D., Axworthy D.B., Baillie T.A., Farmer P.B., Farrow K.C., Gescher A., Kestell P., Pearson P.G., Shaw A.J. (1987). Metabolism of N-methylformamide in mice: primary kinetic deuterium isotope effect and identification of S-(N-methylcarbamoyl)glutathione as a metabolite. J. Pharmacol. Exp. Ther. 242(1), 312–319.
  • 80. Tofilon P.J., Vines C.M., Milas L. (1986). N-Methylformamide-mediated enhancement of in vitro tumor cell chemosensitivity. Cancer Chemother. Pharmacol. 17(3), 269–273.
  • 81. Tulip K., Nicholson J.K., Timbrell J.A. (1986). Comparison of N-methylformamide-induced hepatotoxicity and metabolism in rats and mice. Adv. Exp. Med. Biol. 197, 941–950.
  • 82. Tulip K., Timbrell J.A. (1988). Comparative hepatotoxicity and metabolism of N-methylformamide in rats and mice. Arch. Toxicol. 62(2–3), 167–176.
  • 83. Vogel W.C., Forastiere A.A., Natale R.B., Takasugi B.J., Schnur G. (1987). Phase II trial of N-methylformamide in advanced head and neck cancer. Invest. New Drugs. 5(2), 203–206. 84. Whitby H., Gescher A., Levy L. (1984). An investigation of the mechanism of hepatotoxicity of the antitumour agent N-methylformamide in mice. Biochem. Pharmacol. 33(2), 295–302.
  • 84. Wiemann M.C., Cummings F.J., Posner M.R., Posner M.R. et al. (1985). Phase I clinical and pharmacological trial of oral N-methylformamide (NMF). Proc. Am. Soc. Clin. Oncol. 4, 38 (abstr.) [cyt. za: Clagett-Carr i in. 1988].
  • 85. Wiemann M.C., Michael P., Cummings F.J. et al. (1984). Phase I clinical and pharmacological studies of orally administered N-methylformamide (NMF). Proc. Am. Soc. Clin. Oncol. 3, 36 (abstr.) [cyt. za: Clagett-Carr i in. 1988].
Uwagi
Opracowanie rekordu ze środków MNiSW, umowa Nr 461252 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2021).
Typ dokumentu
Bibliografia
Identyfikator YADDA
bwmeta1.element.baztech-af5f8e9e-c082-4fef-b42a-bd61a0145ae1
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.